ArticleACS nano2011
Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model.
Article in ACS nano, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 497 citations in OpenAlex.
- The application of ICG-based photodynamic therapy combined with nanotechnology in tumor treatment.RSC advances · 2026Review
- Targeted drug delivery systems for pancreatic cancer therapy: advances, challenges, and future perspectives.Frontiers in immunology · 2026Review
- Hyaluronic Acid-Modified Nanoparticles Loaded with Cabazitaxel: A Promising Nanomedicine for Malignant Prostate Tumors.Current drug delivery · 2026Article
- Toxicological and anti-inflammatory activities of doxorubicin loaded onto pH-sensitive poly(β-amino ester) modified mesoporous silica nanoparticles in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Quercetin combined with shTERT induces apoptosis in ovarian cancer via the P53/Bax pathway, and RGD-MSN/QR/shTERT nanoparticles enhance the therapeutic efficacy.Journal of nanobiotechnology · 2025Article
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- Improved Therapeutic Efficacy: Liposome-Coated Mesoporous Silica Nanoparticles Delivering Thymoquinone to MCF-7 Cells.Current drug delivery · 2025Article
- Drug Release via Ultrasound-Activated Nanocarriers for Cancer Treatment: A Review.Pharmaceutics · 2024Review
- Article
- Surface Modification of Mesoporous Silica Nanoparticles for Application in Targeted Delivery Systems of Antitumour Drugs.Polymers · 2024Review
- Potential Applications and Additive Manufacturing Technology-Based Considerations of Mesoporous Silica: A Review.AAPS PharmSciTech · 2023Review
- Article
- Toxicity evaluation of silica nanoparticles for delivery applications.Drug delivery and translational research · 2023Review
- pH-responsive upconversion mesoporous silica nanospheres for combined multimodal diagnostic imaging and targeted photodynamic and photothermal cancer therapy.bioRxiv : the preprint server for biology · 2023Article
- Dual Anticancer and Antibacterial Properties of Silica-Based Theranostic Nanomaterials Functionalized with Coumarin343, Folic Acid and a Cytotoxic Organotin(IV) Metallodrug.Pharmaceutics · 2023Article
- Effect of the Silica-Magnetite Nanocomposite Coating Functionalization on the Doxorubicin Sorption/Desorption.Pharmaceutics · 2022Article
- Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?Chemical Society reviews · 2022Review
- Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue.Cancers · 2022Review
- Iron oxide nanoparticles as a drug carrier reduce host immunosuppression for enhanced chemotherapy.Nanoscale · 2022Article
- Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications.Journal of nanobiotechnology · 2022Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
A key challenge for improving the efficacy of passive drug delivery to tumor sites by a nanocarrier is to limit reticuloendothelial system uptake and to maximize the enhanced permeability and retention effect. We demonstrate that size reduction and surface functionalization of mesoporous silica nanoparticles (MSNP) with a polyethyleneimine-polyethylene glycol copolymer reduces particle opsonization while enhancing the passive delivery of monodispersed, 50 nm doxorubicin-laden MSNP to a human squamous carcinoma xenograft in nude mice after intravenous injection. Using near-infrared fluorescence imaging and elemental Si analysis, we demonstrate passive accumulation of ∼12% of the tail vein-injected particle load at the tumor site, where there is effective cellular uptake and the delivery of doxorubicin to KB-31 cells. This was accompanied by the induction of apoptosis and an enhanced rate of tumor shrinking compared to free doxorubicin. The improved drug delivery was accompanied by a significant reduction in systemic side effects such as animal weight loss as well as reduced liver and renal injury. These results demonstrate that it is possible to achieve effective passive tumor targeting by MSNP size reduction as well as by introducing steric hindrance and electrostatic repulsion through coating with a copolymer. Further endowment of this multifunctional drug delivery platform with targeting ligands and nanovalves may further enhance cell-specific targeting and on-demand release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.